GlassScriptPhysician profile
Diana J Holte
NPI 1114319605
$1,893.99
in general payments reported to CMS, 2019-2025
24 companies · $28.24 in 2025
The $28.24 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,205 · 2023: $256 · 2024: $405 · 2025: $28.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $304.94 | 2024 | Voquezna |
| Pfizer INC. | $236.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $215.18 | 2021-2024 | Farxiga, Breztri |
| Abbvie INC. | $175.25 | 2021-2024 | |
| Horizon Therapeutics Plc | $151.04 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.56 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $123.10 | 2021 | |
| Lilly USA, LLC | $104.40 | 2021-2024 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $64.40 | 2021 | |
| Novo Nordisk INC | $54.33 | 2021-2023 | Rybelsus |
| Merck Sharp & Dohme LLC | $49.96 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.99 | 2023 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $36.98 | 2021 | |
| Allergan, INC. | $35.66 | 2021 | |
| Eisai INC. | $30.48 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.24 | 2025 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $22.01 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $15.53 | 2021 | |
| Currax Pharmaceuticals LLC | $14.50 | 2024 | Contrave |
| Kowa Pharmaceuticals America, INC. | $12.70 | 2021 | |
| Alfasigma USA, INC. | $11.87 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.38 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.18 | 2021 | |
| Genentech USA, INC. | $2.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Holte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.